Clinical Trial Update: Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating vedolizumab IV 300 mg for fistulizing Crohn's disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Vedolizumab (vedolizumab)

Snippet

Sponsor: Takeda | Conditions: Crohn's Disease | Phase 4 | Status: COMPLETED | Results posted: 2019-09-25